Tajikistan Medical Device Registration 2026: Applicant, Certificate Holder and Foreign Manufacturer

1. Key takeaways

The registration chain in Tajikistan involves three categories of actors with different legal positions: the manufacturer is the source responsible party, the applicant is the submitting party, and the registration certificate holder is the party bearing responsibility. Article 17(2) provides that, for registration purposes, the manufacturer or its authorized person (applicant) shall submit the prescribed list of necessary documents to the State Supervisory Body for Pharmaceutical Activity in electronic or written form; Article 17(6) provides that the registration certificate holder bears responsibility for the quality, effectiveness and safety of the registered materials. When designing the entity architecture for a Tajikistan project, GRZAN positions these three roles separately rather than conflating them.

2. Legal basis

3. Expert insights

Insight 1: Article 17(2) places the manufacturer or its authorized person side by side, reserving an authorization pathway for foreign enterprises. The wording is the manufacturer or its authorized person (applicant), which means a foreign manufacturer need not submit in person and may act through an authorized person. However, the provision itself does not specify the qualification requirements for the authorized person (whether it must be a Tajik resident, whether it must be a legal entity, whether it must hold a license). The approach of GRZAN is to use Article 26(3), item 3 as corroborating evidence — that paragraph lists foreign manufacturers and their authorized persons among the parties entitled to import and export, showing that the authorized person mechanism is recognized within the framework of Law No. 1893; as for the specific qualifications of the authorized person, one must turn to the registration procedure documents developed by the Ministry of Health.

Insight 2: Responsibility falls on the registration certificate holder, not the applicant. Article 17(6) explicitly allocates responsibility for quality, effectiveness and safety to the registration certificate holder. This is critical in contract design: when a foreign manufacturer signs with a local partner, if the agreement provides that the local party acts as registration certificate holder, the statutory responsibility under Article 17(6) falls on the local party; otherwise it is borne by the foreign manufacturer. Responsibility is bound to the certificate-holding entity and cannot be countered by internal agreements, although internal recourse may be agreed contractually.

Insight 3: The confidentiality clause of Article 17(7) is a double-edged sword. That paragraph allows information on registered products to be designated as confidential, provided the formulation or composition is not known to industry peers and the manufacturer keeps it confidential, or the confidentiality is determined by its commercial value. For device companies, the practical value of this provision is that technical formulations, software algorithms and core process parameters have room for a confidentiality application. Note, however, that once confidential status is granted, Article 17(8) still requires registered products to be entered in the State Register of Medicines — the boundary between confidentiality and disclosure must be clarified with the competent authority at the time of submission.

Insight 4: Item 7 of Article 9 locks the inspection object onto subjects of pharmaceutical activity. Article 1, item 38 defines subjects of pharmaceutical activity as natural persons and legal entities engaged in pharmaceutical activity within Tajikistan, while Article 1, item 12 defines pharmaceutical activity broadly to include research and development, production, storage, transport, state registration, standardization and quality control, labeling, trade, advertising and use. The consequence is that once a foreign manufacturer conducts state registration through an authorized person, it may enter the purview of the supervisory body, since it engages in pharmaceutical activity of engaging in pharmaceutical activity. This should be considered in advance when designing the local representative architecture.

4. Practical recommendations

1. Decide the certificate holder before deciding the applicant. GRZAN recommends that foreign manufacturers clarify at the project initiation stage whether the registration certificate will be held by a foreign entity or by a local partner. This determines the allocation of statutory responsibility under Article 17(6), and also determines who bears subsequent obligations for changes, market withdrawal and pharmacovigilance reporting.
2. List the submission powers of Article 17(2) item by item in the authorization letter. The authorization letter should enumerate: submitting the registration application on behalf of the manufacturer, signing documents, receiving official correspondence, handling deficiency requests, and processing changes and re-registration. The list of powers should conform to the text format required by the Ministry of Health registration procedure documents.
3. Assess whether to apply for confidential status under Article 17(7). For products involving core processes or algorithms, GRZAN recommends submitting the confidentiality application simultaneously with the dossier, stating which of the two conditions of that paragraph is satisfied.
4. Agree on an internal recourse mechanism for Article 17(6) responsibility between the manufacturer and the certificate holder. Statutory responsibility cannot be transferred by agreement, but compensation arrangements may be agreed between the manufacturer and the certificate-holding party, keeping risk within a controllable range.

5. Verification checklist

• □ Clarified the registration certificate holder (determines allocation of statutory responsibility under Article 17(6))
• □ Confirmed the applicant is the manufacturer or its authorized person (Article 17(2))
• □ Listed submission, signing, document receipt, deficiency handling, change and re-registration powers item by item in the authorization letter
• □ Assessed whether to apply for confidential status under Article 17(7) and its conditions
• □ Agreed an internal recourse mechanism for Article 17(6) responsibility between the manufacturer and the certificate holder
• □ Confirmed the authorized person meets the qualification requirements in the Ministry of Health registration procedure documents
• □ Assessed whether the foreign manufacturer enters the inspection scope of Article 9, item 7 through state registration activity

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three points: first, distinguishing the different legal status of each market within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states offering a dual choice between the national track and the union track; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan are outside the union framework and must follow purely national procedures. Second, local authorized representative services, acting as the statutory representative of manufacturers in these countries and undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com